Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
Filings by filing date
News
Biz Brief
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 414 N Orleans St Ste 502 CHICAGO IL 60654-4498 |
| Tel: | N/A |
| Website: | www.medite-group.com |
| IR: | See website |
| Key People | ||
| Michaela Ott Chief Operating Officer | Jeff Rencher Chief Marketing and Business Development Officer | |
| Business Overview |
| MEDITE Cancer Diagnostics, Inc. (MEDITE) is a medical technology company specialized in the development, manufacturing, and marketing of premium medical devices, consumables and molecular biomarkers for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. The Company also develops, manufactures, markets, and sells MEDITE branded products (instruments and consumables), in the areas of histology and cytology. The Company has a distribution network to over 80 countries and a range of products for anatomic pathology, histology and cytology laboratories available for sale. The Company's subsidiaries consist of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany and MEDITE Lab Solutions Inc. |
| Financial Overview |
| For the nine months ended 30 September 2018, Medite Cancer Diagnostics Inc revenues increased 27% to $6.2M. Net loss applicable to common stockholders decreased 35% to $2.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development, decrease of 40% to $705K (expense), Selling decrease of 7% to $3M (expense). |
| Employees: | 5 as of Mar 27, 2014 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $6.62M as of Sep 30, 2018 |
| Annual revenue (TTM): | $8.13M as of Sep 30, 2018 |
| EBITDA (TTM): | -$3.73M as of Sep 30, 2018 |
| Net annual income (TTM): | -$5.42M as of Sep 30, 2018 |
| Free cash flow (TTM): | -$5.30M as of Sep 30, 2018 |
| Net Debt Last Fiscal Year: | $5.65M as of Sep 30, 2018 |
| Shares outstanding: | 86,723,700 as of Nov 10, 2018 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |